LGVN Longeveron
- 2.060
- +0.010+0.49%
- 2.090
- +0.030+1.46%
Longeveron News
Buy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial Progress
Express News | Longeveron Inc - Alignment With FDA on Elpis II Primary and Secondary Endpoints
Express News | Longeveron Inc - Company to Submit Sap and Cmc Readiness Plan to FDA
Express News | Longeveron® Announces Positive Type C Meeting With U.S. FDA Regarding Pathway to Bla for Lomecel-B™ in Hypoplastic Left Heart Syndrome (Hlhs)
Beyond The Numbers: 4 Analysts Discuss Longeveron Stock
Maxim Group Maintains Longeveron(LGVN.US) With Buy Rating, Cuts Target Price to $6
Express News | Longeveron Inc : Maxim Group Cuts Target Price to $6 From $15
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Longeveron Reports Q2 Results
Buy Rating Reaffirmed for Longeveron on Strong Clinical Trial Prospects and Regulatory Advantages
Longeveron: Cash and Cash Equivalents Expected to Be Sufficient to Fund Co Through 4Q of 2025 >LGVN
Longeveron Q2 2024 GAAP EPS $(1.83) Up From $(2.67) YoY, Sales $468.00K Miss $525.00K Estimate
Earnings Flash (LGVN) LONGEVERON Reports Q2 Revenue $468,000, Vs. Street Est of $0.5M
Longeveron | 10-Q: Q2 2024 Earnings Report
Express News | Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
Press Release: Longeveron(R) Announces Second Quarter 2024 Financial Results and Provides Business Update
Longeveron to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
Express News | Longeveron Has Been Granted Australian Patent Number 2017213812 Titled "Mesenchymal Stem Cells As Vaccine Adjuvants And Methods For Using The Same"
H.C. Wainwright Maintains Longeveron(LGVN.US) With Buy Rating, Maintains Target Price $10
Analysis
Price Target
No Data
No Data